Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020
SAN DIEGO--(BUSINESS WIRE)--Nov 6, 2020--
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2020 financial results on Tuesday, November 10, 2020.
In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, November 10, 2020, to discuss the Company’s financial results and provide a corporate update.
Conference ID: 2879501
Domestic Dial-in Number: (833) 646-0603
International Dial-in Number: (929) 517-9782
Live Webcast: https://edge.media-server.com/mmc/p/e6ppaa7u
A replay of the audio webcast will be available for 30 days on the Investors section of the Company’s website, www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201106005093/en/
CONTACT: For Investors and Media:
Bryan Giraudo, Chief Financial Officer
Gossamer Bio Investor Relations
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL FINANCE ONCOLOGY HEALTH PROFESSIONAL SERVICES CLINICAL TRIALS OTHER HEALTH
SOURCE: Gossamer Bio, Inc.
Copyright Business Wire 2020.
PUB: 11/06/2020 07:07 AM/DISC: 11/06/2020 07:07 AM